What is Revolution Medicines Inc Annual Net Profit?

Revolution Medicines Inc Annual Net Profit fell 37.52% in the last year to $600.09 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

What is Revolution Medicines Inc Price to Earning Ratio?

Revolution Medicines Inc Price to Earning Ratio is -9.64, which is negative.

What is Revolution Medicines Inc Stock Price?

Revolution Medicines Inc Stock Price fell 0.45% and outperformed its sector by 3.3% in the past year.

What is Revolution Medicines Inc Quarterly Net profit?

Revolution Medicines Inc Quarterly Net profit fell 20.45% YoY to $194.57 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

What is Revolution Medicines Inc Debt to Equity Ratio?

Revolution Medicines Inc Debt to Equity Ratio of 0.06 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Revolution Medicines Inc Return on Equity(ROE)?

Revolution Medicines Inc Return on Equity(ROE) for the last financial year was -29.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Revolution Medicines Inc Mutual Fund Holding?

Revolution Medicines Inc Mutual Fund Holding increased by 0.29% in the last quarter to 60.8.

What is Revolution Medicines Inc Promoter Share Holding?

Revolution Medicines Inc Promoter Share Holding increased by 0.37% in the most recent quarter to 6.5%.

What is Revolution Medicines Inc Institutional Holding?

Revolution Medicines Inc Institutional Holding remained the same in the last quarter at 104.4%.

How is the Revolution Medicines Inc today?

The Revolution Medicines Inc today is trading in the down by -0.86% at 31.13.

How has Revolution Medicines Inc performed historically?

The Revolution Medicines Inc is currently trading down -0.86% on an intraday basis in the past week the index fell -11.96%. The index has been down -29.78% in the past quarter and fell -0.45% in the past year. You can view this in the overview section.

Revolution Medicines Inc XNAS: RVMD

Revolution Medicines Inc Live Share Price Today, Share Analysis and Chart

Name: Revolution Medicines Inc: Is Infosys Ltd. worth buying?
Item: Revolution Medicines Inc
Rating: 0.84866675
Author: Trendlyne DVM scores

Download real time

31.13 -0.27 (-0.86%)

New 52W Low in past week

2.8M XNAS Volume

XNAS 08 Apr, 2025 5:30 PM (EDT)

Revolution Medicines Inc Key Metrics

My Metrics

Select

Market Capitalization Market Runner Up Unavailable in chosen country	5,787.5
PE TTM Negative PE TTM Unavailable in chosen country	-9.6
PEG TTM High in industry Unavailable in chosen country	0.3
Price to Book Below industry Median Unavailable in chosen country	2.6
Institutional holding current Qtr % Market Leader Unavailable in chosen country	104.4
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-100
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-100
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-20.4
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-37.5
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-22.9
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-29.3
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-26

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

5.7 / 100

Technically Bearish

28.3 / 100

1Yr Price target upside is 136%

14 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Revolution Medicines Inc Stock Price Analysis

Day Price Range -0.9% 1 Day return Unavailable in chosen country	31.1 (LTP) 30.733.2 LowHigh
Week Price Range -12.0% 1 Week return Unavailable in chosen country	31.1 (LTP) 29.236 LowHigh
Month Price Range -20.6% 1 Month return Unavailable in chosen country	31.1 (LTP) 29.240.9 LowHigh
52 Week Price Range -0.4% 1 Year return Unavailable in chosen country	31.1 (LTP) 29.262.4 LowHigh

View full Share Price History

Revolution Medicines Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Revolution Medicines Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-4

Avg. Estimate

-4

Low Estimate

-4.6

High Estimate

-3.3

Current EPS

Avg. Estimate

Consensus Recommendation

15 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 15 analysts for Revolution Medicines Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Revolution Medicines Inc Stock Analysis

Revolution Medicines Inc stock analysis with key metrics, changes, and trends.

Revolution Medicines Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$600.09 M	37.52%	negative	Annual Net Profit fell 37.52% in the last year to $600.09 M. Its sector's average net profit growth for the last fiscal year was -32.62%.
Price to Earning Ratio	-9.64	-	negative	Price to Earning Ratio is -9.64, which is negative.
Stock Price	$31.13	-0.45%	positive	Stock Price fell 0.45% and outperformed its sector by 3.3% in the past year.
Quarterly Net profit	$194.57 M	20.45%	negative	Quarterly Net profit fell 20.45% YoY to $194.57 M. Its sector's average net profit growth YoY for the quarter was -47.55%.
Debt to Equity Ratio	0.06	-	positive	Debt to Equity Ratio of 0.06 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-29.33 %	-29.33%	negative	Return on Equity(ROE) for the last financial year was -29.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	60.80 %	0.29%	positive	Mutual Fund Holding increased by 0.29% in the last quarter to 60.8.
Promoter Share Holding	6.50 %	0.37%	positive	Promoter Share Holding increased by 0.37% in the most recent quarter to 6.5%.
Institutional Holding	104.40 %	0%	neutral	Institutional Holding remained the same in the last quarter at 104.4%.

VIEW LESS

Loading data..

Revolution Medicines Inc - Company Profile

What does Revolution Medicines Inc do?

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Gross Remuneration

2024

Gross Remuneration

Year

Revolution Medicines Inc Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Revolution Medicines Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

RoA Annual %

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Revolution Medicines Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Revolution Medicines Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Revolution Medicines Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 15 analysts for Revolution Medicines Inc is STRONG BUY

Revolution Medicines Inc Stock Analysis

Revolution Medicines Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 37.52% in the last year to $600.09 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

Price to Earning Ratio is -9.64, which is negative.

Stock Price fell 0.45% and outperformed its sector by 3.3% in the past year.

Quarterly Net profit fell 20.45% YoY to $194.57 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

Debt to Equity Ratio of 0.06 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -29.33%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.29% in the last quarter to 60.8.

Promoter Share Holding increased by 0.37% in the most recent quarter to 6.5%.

Institutional Holding remained the same in the last quarter at 104.4%.

Revolution Medicines Inc - Company Profile

What does Revolution Medicines Inc do?

Revolution Medicines Inc Management structure

Dr. Mary Pinder-Schenck, M.D.

Senior Vice President, Head of Medical Affairs

Mr. Ryan Asay

Senior Vice President, Corporate Affairs

Dr. Mason Shih, M.D.

Senior Vice President, Head of Drug Safety

Dr. Jing Yi, PhD

Senior Vice President, Head of Program Leadership.

Dr. Mark A. Goldsmith, M.D., PhD

President, Chief Executive Officer and Chairman of the Board

Mr. Jack Anders

Chief Financial Officer and Principal Accounting Officer

Revolution Medicines Inc Board of directors

Mr. Frank K. Clyburn, Jr

Independent Director

Mr. Alexis A. Borisy, A.M.

Lead Independent Director

Dr. Sandra J. Horning, M.D.

Independent Director

Dr. Thilo Schroeder, PhD

Independent Director

Dr. Lorence H. Kim, M.D.